Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 1.00 |
| ▸ | PARK7 | Q99497 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 8/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1061089 | 1.00 | TRPA1 (1.00) | TRPA1PARK7EGFRCHRM5ALDH1A1 | |
| SCHEMBL12930205 | 0.85 | TRPA1 (0.74) | TRPA1PARK7EGFRCHRM5ALDH1A1 | |
| SCHEMBL12930306 | 0.85 | TRPA1 (0.74) | TRPA1ALDH1A1ALDH3A1ALDH2CDC25A | |
| SCHEMBL1061470 | 0.84 | TRPA1 (0.72) | TRPA1ALDH1A1ALDH3A1ALDH2CDC25A | |
| SCHEMBL1061471 | 0.84 | TRPA1 (0.72) | TRPA1ALDH1A1ALDH3A1ALDH2CDC25A | |
| SCHEMBL12930285 | 0.82 | TRPA1 (0.69) | TRPA1PARK7CHRM5CDC25A | |
| SCHEMBL13652120 | 0.81 | TRPA1 (0.68) | TRPA1ALDH1A1ALDH3A1ALDH2CDC25A | |
| SCHEMBL29260673 | 0.81 | TRPA1 (0.67) | TRPA1PARK7EGFRCHRM5ALDH1A1 | |
| SCHEMBL29260675 | 0.81 | TRPA1 (0.67) | TRPA1PARK7EGFRCHRM5ALDH1A1 | |
| SCHEMBL12930312 | 0.80 | TRPA1 (1.00) | TRPA1PARK7CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180015051-A1 | MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR THE TREATMENT OF DIABETIC PATHOLOGIES | BUCK INST RES AGING (US) | 2018-01-18 | — | — | US | claimed |
| US-20110009379-A1 | INDOLINONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-01-13 | — | — | US | claimed |
| EP-2261206-A1 | INDOLINONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-12-15 | — | — | EP | claimed |
| US-20180015051-A1 | MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR THE TREATMENT OF DIABETIC PATHOLOGIES | BUCK INST RES AGING (US) | 2018-01-18 | — | — | US | disclosed |
| US-20110009379-A1 | INDOLINONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2261206-A1 | INDOLINONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015051-A1 | MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR THE TREATMENT OF DIABETIC PATHOLOGIES | TRPA1, TRPV1, TRPM2 | TRPA1 1/4885PARK7 3704/4885EGFR 4019/4885 |
| US-20110009379-A1 | INDOLINONE COMPOUND | TRPA1, TRPV1, TRPV6 | TRPA1 1/4885PARK7 516/4885EGFR 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.